Japanese pharmaceutical giant Takeda Pharmaceutical Co. Ltd. booked a nearly 46% year-over-year increase in its net profit for the nine-month period ended Dec. 31, 2016.
The company posted ¥165.7 billion, or ¥212 per share, in net profit for the period, which compares to ¥113.6 billion, or ¥145 per share, in the prior-year period.
Core earnings were down, however, by 14.8% year over year to ¥228.3 billion. On a per-share basis, core EPS was down 4.4% year over year to ¥229.
Takeda generated ¥1.315 trillion in revenue during the nine months ended Dec. 31, 2016, a 5.6% decrease year over year.
The company also increased its financial guidance for the fiscal year to account for the ARIAD acquisition.
The pharma giant now expects to post ¥93 billion, or ¥119 per share, in net profit for the fiscal year ending March 31, 2017, as opposed to ¥91 billion, or ¥116 per share, previously.
As of Jan. 31, US$1 was equivalent to 112.39 Japanese yen.